DLBCL case summary.xls

Currently risk factors associated with chemotherapy-induced thrombocytopenia(CIT) in patients with Diffuse Large B Cell Lymphoma (DLBCL) is still undefined. Our research aims to analyse the effects of risk factors on thrombocytopenia. Moreover, it also aims to analyse the optimal threshold for infusion platelets of CIT patients who have received platelet transfusions.We conducted a retrospective analysis of 523 patients with DLBCL from 2011 to 2013 . Clinical and demographic parameters were extracted and analyse the risk factors associated with CIT. The threshold for platelet transfusions in DLBCL patients with central venous catheter (CVC) was evaluated.227 (43.4%) DLBCL patients had thrombocytopenia and 63 (12%) had thrombocytopenia without concomitant cytopenias. We identified that the choice of chemotherapy regimen was positively correlated with thrombocytopenia (p <0.001). The chemotherapy regimens that are most likely to result in thrombocytopenia were DHAP (92.3%), ICE (89.7%), GDP (89.7%) and Gemox (69%) respectively. Aside from this, high LDH (P = 0.006) and Ann Arbor Stage III / IV (P = 0.025) were determined to be risk factors leading to thrombocytopenia. 40 patients (17.6%) had transfused platelets, and all of them were placed in the central venous. The high-threshold group (Platelet count PC≤20×10⁹/L) has a significant lower amount of platelet transfusions than the low-threshold group (PC≤10×10⁹/L). The platelet transfusion amount was1.44 ± 0.77 vs 2.05 ± 1.13(p = 0.047).In conclusion,The chemotherapy regimens that were DHAP, ICE, GDP and Gemox can easily lead to thrombocytopenia. A high level of LDH in peripheral blood and Ann Arbor Stage III / IV are also risk factors accountable for thrombocytopenia. A 20×10⁹/L prophylactic platelet transfusion threshold value is safe and effective and a better choice for the DLBCL patients with CVC.